Episode

E134: Brepocitinib in Dermatomyositis (VALOR)

Podcast: The Evidence Based Rheumatology Podcast
Published: Apr 17, 2026
Duration seconds: 898
Processing state: not_requested
Canonical source: https://msputman.podbean.com/e/e134-brepocitinib-in-dermatomyositis-valor/
Audio: https://mcdn.podbean.com/mf/web/yz9465wkvuzhurxw/e134.mp3
JSON: /v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e134-brepocitinib-in-dermatomyositis-valor
Markdown: /podcast/the-evidence-based-rheumatology-podcast-1130175/e134-brepocitinib-in-dermatomyositis-valor.md

Actions

POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e134-brepocitinib-in-dermatomyositis-valor/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e134-brepocitinib-in-dermatomyositis-valor.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option. Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531 JC Companion: https://autoimmunedevreport.substack.com/